Download Слайд 1 - Promo-med

Innovative approach to life
Our mission:
Giving a part of ourselves, we give people an
opportunity to live a productive life. Our innovative
approach allows us to create effective solutions that
provide confidence in the future. We are the team of
like-minded people who help people live and think in
a different way!
Our mission:
Giving a part of ourselves, we give people an opportunity to live a productive life. Our innovative
approach allows us to create effective solutions that provide confidence in the future. We are the
team of like-minded people who help people live and think in a different way!
Dear friends,
Promo-Med LLC. Company was established in September 2005 and today it is one of the most
dynamic in the pharmaceutical industry. The Company’s goal is to create and maintain an image of
the Russian pharmaceutical brand as a new category of product, which is of high quality, accessible,
trusted by both doctors and patients. The Company closely monitors the development of the Russian
pharmaceutical market and keeps track of the most promising segments of the market, constantly
enriching its portfolio of products. Promo-Med LLC. is a highly effective and flexible Company that
allows it to respond quickly to changes or demands of the current pharmaceutical market,
performing with the greatest benefit to investors and partners.
Elena Palevskaya
CEO
Promo-Med is a new-generation innovative company introducing its
European quality medicines at fair price to the Russian market
The Company was founded in September, 2005 by Russian and foreign investors.
Company’s first steps started from the development, registration and production of medicinal products Revokarin® and Neosmektin® in 2005.
In 2006 – just within 10 months of Neosmektin® lauch – the drug has conquered 3.4% of the market share of its main competitor – Smecta (manufactured by
Beaufour Ipsen International, France). In 2006 Neosmektin® was sold successfully to Pharmstandard OJSC.
Meridia patent expired on the 18th of December 2007. And on the 19th of December 2007 Reduxin®, a generic, showed up at retailers in Russia.
Trademark Reduxin® made a breakthrough, having been moved from the 14th in 2008 to the 6th place in 2009 in terms of volume sales in cash equivalent
among TOP 100 Trademarks in Retail Industry on the Russian pharmaceutical market.
In 2009 a new cardiac drug Valsaforce®, the first generic of the sartan, was launched.
In March 2009 the Company’s CEO Palevskaya E.Yu. entered TOP 20 Most Influential Women in Business in the annual project Careers.
In 2010 Medomexi® , a new multi-purpose cytoprotector for the neurogroup, was launched on the market.
In 2011 a series of new drugs were launched:
Melfor® - multi-purpose cytoprotector for the cardiac group.
Raylis® – medicine for the treatment and prevention of erectile dysfunction.
Thus, in 2011 the Company gained a unique business package: Medomexi® (ampoules+tablets) and Melfor® (ampoules + capsules).
The Company also acquired a joint possession right for brand Taufon.
Mission
The Promo-Med mission is to create and maintain the image of the Russian
pharmaceutical brand as a new product category – high quality, affordable, reliable
among doctors and patients.
Corporative values:
Complete professionalism, liability, innovativeness and professionalism again.
4 components of our success:
Ambitious and professional team.
Excellent knowledge of the pharmaceutical market.
Personal scientific research.
Promptness of making solutions.
Distribution
The Company’s medicines are available in 87 Russian cities:
Moscow, St. Petersburg, Nizhny Novgorod, Murmansk, Novosibirsk, Ekaterinburg, Samara,
Krasnodar, Rostov-on-Don, Veliky Novgorod, Tula, Omsk, Volgograd and others
The company has a broad network of field sales representatives all over
the directions across the entire territory of Russia
Areas of focus
Our knowledge and resources are focused on 6 main therapeutic groups:
ENDOCRINOLOGY
UROLOGY
GASTROENTEROLOGY
CARDIOLOGY
GYNECOLOGY
NEUROLOGY
We produce innovative and effective drugs with improved safety profiles and more
convenient administration.
We continuously conduct all-Russian clinical trials and non-intervention studies of our
products to assess efficiency and safety of our products.
Research
Efficiency and safety of the drugs manufactured by our company are confirmed by authoritative clinical trials:
“Experience in Reduxin® (sibutramin) in patients with metabolic syndrom” (S.А. Butrova, М.А. Berkovskaya, К.А. Komshilova)
Federal State Institute Endocrinology Research Centre RMT (Moscow).
“Reduxin® is a new solution for old problems!” (Т.Yu. Demidova, MD, Professor of Endocrinology and Diabetology Department
with endocrine surgery of Russian Medical Academy of Post-Graduate Education of Roszravnadzor).
“Dynamics of body weight reduction in obese patients (12 weeks)” (Professor А.М. Mkrtumyan, Е.V. Biryukova, N.V. Markina)
Endocrinology and Diabetology Department of Moscow State University of Medicine and Dentistry (MSUMD).
“Dynamics of BMI in patients with type 2 diabetes and obesity” (Professor М.B. Antsiferov) Moscow endocrinological
dispensary.
“Open-label, single-arm, multicentere clinical study of efficacy and safety of Raylis® in patients with mild to moderate erectile
dysfunction” (Professor D.Yu. Pushkar, MD) Urology Department of the Faculty of Medicine (MSUMD).
“Clinical efficiency and safety of Valsaforce® in patients with hypertension and chronic renal disease” (M.L. Maximov,
O.V. Dralova, A.S. Ermolaeva ) Clinical Pharmacology and Propedeutics Department of the Faculty of Medicine of The I.M.
Sechenov Moscow Medical Academy.
Achievements
Annual increase of the Company’s sales is more than 100% grouse
from 2009 to present time
In 2006 – just within 10 months of Neosmektin® launch — the drug has conquered 3.4% of the market share of its main
competitor — Smecta (manufactured by Beaufour Ipsen International, France).
In March 2009 the Company’s CEO Palevskaya E.Yu. entered TOP 20 Most Influential Women in Business in the annual
project Careers.
On April 2011, our company became a winner of the All-Russian Economic Project Leaders of modernization in a
nomination The Enterprise of Year 2011.
Pharmexpert Analytics and Consulting LLC. selected TM Reduxin® the Month’s Best drug of July 2011 as it demonstrated
the best growth of sales volume of all Russian drugs among TOP 100 Tradenames in Retail Industry on the pharmaceutical
market. Sales gain of Reduxin® in May in the current year compared to 2011 was +73.7% and +51.2% in monetary terms and
in natural, respectively.
A new production protection system has been created. Each hologram has its own unique code. This code is essential for
the inspections aimed at products’ identification, monitoring and protection.
In 2011 Reduxin® entered TOP 10 Best Volume Sales (in USD mln) in retail industry of the Russian pharmaceutical market
for the first half of the year, according to Pharmexpert Analytics and Consulting LLC.
Professional Development
Our cooperation with Brand Learning started in September 2011 with the
development of marketing skills and establishment of corporate culture.
Together we share the importance of forming the organization which is customeroriented, as well as the development of marketing potential. Together we transform
marketing skills into our company’s performance by developing and training staff to
use new approach to create successful brands.
Partners
Общество
эндокринологов
Success factors
Professional team.
Creation of a unique marketing strategy, comprehensive market analysis, clinical trials, studying
analogue drugs and substitutes, followed by thorough branding and positioning of the products.
All products promoted by the Company are manufactured from the first-grade imported raw materials
at sites being adequately inspected and selected and having advanced production facilities.
All products are manufactured according to GMP standards, which imply strict quality control at each
process step.
Comprehensive programs starting from the idea up to the introduction of a new product to the market.
Training the Company’s employees with attraction of specialists of European Marketing Academy Brand
Learning.
Extensive support from our partners.
Program Supervisor:
All-Russia Observational Non-Interventional
Program of Reduxin® Safety Monitoring
(VESNA):
chief endocrinologist of Russia
6 months — 50 000 patients
36 cities of Russia
1 093 healthcare facilities
2 071 doctors
Efficiency Analysis:
Safety Monitoring:
Anthropometric data over time (weight;
waist, hip, arm, neck circumferences).
BMI over time.
Eating behavior dynamics.
Quality of life and personal well-being
assessment (questionnaire).
Cardiovascular value control:
Blood pressure dynamics.
Heart rate.
ECG.
Laboratory values:
Blood plasma lipid profile.
Plastic glucose level.
Total bilirubin.
Total protein.
ALT, AST.
Incidence and type of adverse events
Innovative.
Large-Scale All-Russia Observational Program MARS
Program Primary Objective–monitoring of efficiency of
Raylis® in ‘real-life’ clinical practice settings.
Program Supervisor:
Chief urologist of the RF Ministry of Health Care M.D.
Program participants:
1 000 urologists.
4 600 patients in 36 cities of Russia.
Program objective — 14 000 patients.
Clinical Studies of Taufon for Strengthening the
Position of the Brand - Leader
I. “Randomized, open-label, two-parallel-group, prospective, interventional study of
efficiency and safety of Taufon in patients with dry eye syndrome”.
Primary objective: registration of new indications for Taufon (dry eye syndrome).
Principal Investigator:
Chief ophthalmologist of the RF Ministry of Health Care M.D.
II. “Randomized, open-label, prospective, interventional study of efficiency and safety of Taufon® in
children suffering from traumatic lesions of the cornea in two parallel groups in children suffering from
traumatic lesions of the cornea in two parallel groups”.
Primary objective: registration of new indications for Taufon (pediatric use).
Principal Investigator:
Chief children's ophthalmologist of the RF Ministry of Health Care M.D.
Taufon — Leader of the Russian Market of Eye Drops for
Improved Vision*
PRICE
INCREASE BY
300%
* - monitoring of retail sales in packing in Russia based on Pharmexpert Analytics and Consulting LLC. data
Products
The Company manufactures 6 drug products intended for treatment of endocrine, cardiovascular, neurologic,
ophthalmic, and urological conditions. 2 drug products manufactured by the Company are included in the RF list of
vital and essential medicines. The Company product portfolio includes leading brands for weight-reducing treatment
in Russia - Reduxin®, and the biggest-selling product for cataract conservative treatment - Taufon.
Drug product for treatment obesity – Reduxin®
Antihypertensive drug product – Valsaforce®
Drug product for management of neurological disorders of vascular genesis mainly – Medomexi®
Drug product for improved myocardial metabolic function – Melfor®
Drug product for treatment of ophthalmologic conditions – Taufon
Drug product for treatment of erectile dysfunction - Raylis®
Dietary supplements.
The Company manufactures nutritional supplements for health gain:
Product for eye nutrition – Taufon® Vita
Products for management of age-related changes in joints - Ellastenga® active glucosamine
Reduxin®
Pharmacotherapeutic group: weight-loss medication
Active substance: Sibutramine + microcrystalline cellulose
Reduxin® is the only combination product for the effective treatment of obesity, which consists of two active agents
(sibutramine + MCC), which cause loss of appetite, a sense of fulness, excretion of toxins from the body, a lower
profile of side effects, formation of correct eating habits and, most importantly - reduction of excess body weight.
Presentation:
Capsules 10 mg х 30.
Capsules 15 mg х 30.
Capsules 10 mg х 60.
Capsules 15 mg х 60.
Indications:
Diet-induced obesity obesity with body mass index (BMI) of 30 kg/m2
or more.
Diet-induced obesity with BMI 27 kg/m2 or more, if other risk factors
caused by overweight are present, such as type 2 diabetes or
dyslipoproteinemia (disturbance of lipid metabolism).
Sibutramine binds to the brain’s hunger center, causing the
feeling of hunger to decrease and eliminating a tendency to
overeat (especially for the night, under stress, during PMS for
women). Sibutramine also helps speed up metabolism in brown
adipose tissue and promotes its gradual reduction.
Microcrystalline cellulose is a versatile sorbent that contributes to the
removal of toxins from the body. It provides slow release of
sibutramine from the capsules, thereby protecting the patient from
adverse side effects.
Weight loss is accomplished due to a decrease in appetite and a more
rapid saturation with less food. Caloric value of the daily food
consumption is reduced by 20-25%, which allows you to lose up to 10
or more kg in 3 months.
Valsaforce®
Pharmacotherapeutic group: AT1 receptor blocker
Active substance: Valsartan
Valsartan (Valsaforce®) is a specific antagonist of angiotensin II receptor, designed for oral administration. Unlike many sartans, it is an
active drug form, exerts a selective antagonistic effect on the subtype AT1 receptors. The affinity of valsartan to the subtype AT 1 receptors
is about 20 000 times higher than to the subtype AT2 receptors.
Treatment of patients with hypertension with valsartan causes a decrease in blood pressure not accompanied by changes in heart rate.
Presentation:
Film-coated tablets 80 mg х 28.
Film-coated tablets 160 mg х 28.
Indications:
Hypertension.
Chronic heart failure (NYHA class II to IV) in patients receiving
standard therapy, including diuretics, digitalis preparations, as
well as ACE inhibitors or beta-blockers (not simultaneously).
The use of Valsaforce®:
Significantly reduces the risk of cardiovascular events, including reducing the likelihood of its recurrence in people who have had a stroke
Contributes to regression of left ventricular hypertrophy
Exerts antiatherosclerotic and protective effect on blood vessels
Does not affect the erectile function in men
The drug is well tolerated
Adherence to treatment is much higher when compared with other groups of drugs, not least due to the substantial reduction in the
incidence of cough (from 4.3% for enalapril to 0.7% for Valsaforce®).
Valsaforce® is indicated for disorders of lipid and carbohydrate metabolism, with normal or reduced renal function after a stroke, transient
ischemic attacks with paroxysmal or persistent atrial flutter fibrillation, peripheral circulatory disorders, chronic heart failure, disorders of
erectile dysfunction before or after a complex drug therapy, poor tolerance to the major classes of cardiovascular drugs, or in case of
disease symptoms persisting when those drugs are used.
Medomexi®
Pharmacotherapeutic group: antioxidant
Active substance: Ethylmethylhydroxypyridine succinate
Epoch of neurons revival
Medomexi® has evident antioxidant and antihypoxic activity
influencing on the basic links of pathogenesis of different diseases
related to processes of free radical oxidation
Inhibits the free radical oxidation of membrane lipids, freely
binds the peroxy radicals of lipids.
Increases activity of antioxidant enzymes responsible for
formation and consumption of active forms of oxygen, in
particular superoxide dismutase.
Inhibits synthesis of prostaglandins, prostacyclins, thromboxane
A, and leukotrienes.
Has hypolipidemic activity, decreases specifically total
cholesterol level, low-density lipoproteins, reduces
cholesterol/phospholipid ratio decreasing viscosity of lipid layer.
Presentation:
Intravenous and intramuscular solution 50 mg/ml.
Neutral glass vials. 2 ml x 10.
Neutral glass vials. 5 ml x 5.
Pills 125 mg x 30.
Indications:
Acute Cerebrovascular Events of ischemic type (as a part of
complex therapy).
Circulatory encephalopathy.
Vegetative-vascular dystonia.
Inquietude of neurotic and neurosis-like
conditions.
Mild cognitive impairment of vascular genesis.
Age-related reduced cognitive functions in
elderly people (derangement of memory,
orientation, attention focusing).
Asthenic conditions under the influence of
extreme (stress) factors.
Alcohol abstinence syndrome with prevailing
neurosis-like and vegetative vascular
impairment.
Acute intoxication by antipsychotic drugs.
Medomexi® is an effective drug in the complex
therapy of acute and chronic strokes.
Melfor®
Pharmacotherapeutic group: Metabolic agent for treatment and
prevention of cardiovascular diseases
Active substance: Meldonium
The drug has a pronounced vasodilating action: stimulates vascularization of the myocardium, selectively acts on the area of ischemia.
Inhibits the platelet aggregation.
The drug has a cardioprotective effect: it increases myocardial contractility, normalizes myocardial metabolism by restoring the
equilibrium of processes of oxygen delivery and consumption in the cells.
Presentation:
Capsules 250 mg х 40.
Indications:
Reduced performance efficiency, increased physical activity, to accelerate the
rehabilitation during the post-operative period.
As part of combined therapy of ischemic heart disease, chronic heart failure;
cardialgia in the context of dyshormonal myocardial dystrophy.
As part of combined treatment of acute and chronic forms of cerebrovascular
disease.
Combined therapy of alcohol withdrawal syndrome.
Melfor® is the perfect medication for the combination therapy of cardiovascular
diseases. Due to its metabolic actions, it helps increase the effect of
cardiovascular therapy and restores the effectiveness of the administered
antianginal therapy.
It helps improve the quality of life of patients with angina pectoris, restoring
myocardial performance during ischemia (reduces frequency of painful and
painless angina attacks).
It improves survival after myocardial infarction, reducing the recovery period
after cardiovascular accident.
Effectiveness of Melfor® is tested by athletes who use it before and after
workouts to improve adaptation to physical exertion.
Taufon
Pharmacotherapeutic group: Metabolic agent
Active substance: Taurine 4%
Pharmaceutical form: Eye drops.
Packaging: 10 ml vials.
Taufon (taurin) is a sulphur-containing amino acid that is forming in a body during transformation of cysteine.
Stimulates reparation and regeneration processes during diseases of dystrophic character and diseases following with
sharp impairment of eye tissue metabolism.
Favours normalization of functions of cell membranes, activation of energy and metabolic processes, keeping the
cytoplasm electrolyte concentration due to accumulation of К+ and Са+, improving conditions of nervous impulse
conducting.
Indications:
Corneal dystrophies.
Senile, radiation, traumatic and other types of cataracts.
Corneal traumas (as a stimulator of reparative processes).
Primary open-angle glaucoma in combination with adrenergic blocking agents.
Taufon is a unique metabolic agent which stimulates regenerative processes and improves metabolism of the eye
tissues.
Taufon was manufactured by the ophthalmologists of the leading research center of the country, Federal State
Institution “The Helmholtz Moscow Research Institute of Eye Diseases” and successfully used in Russia and CIS
countries for the treatment of various eye diseases. The use of the drug for more than 30 years confirmed its
high efficacy and good tolerance. The medicine is the best-selling drug for the topical treatment of eye in the
Russian Federation.
Raylis®
Pharmacotherapeutic Group: the drug of vegetable origin for the treatment of erectile
dysfunction
Active ingredients: Panax ginseng root powder, Codonopsis pilar root powder, Panax
pseudoginseng root powder, Astragalus membranaceus root powder, Epimedium extract
Pharmaceutical Form: capsules x 14 x 28.
Composition (1 capsule):
Panax ginseng root powder – 50 mg.
Conodopsis pilar root powder – 50 mg.
Panax pseudoginseng root powder – 50 mg.
Astragalus membranaceus root powder – 10 mg.
Epimedium extract – 150 mg.
F complex of biologically active components of the drug has
a stimulating and tonic effect.
Indications:
Treatment and prevention of erectile dysfunction.
Recovery and enhancement of sexual function.
Stimulation of sexual desire.
Physical and emotional strain.
Recovery after somatic and infectious diseases asthenia.
Raylis® improves erection only when there is sexual stimulation. The drug does not induce spontaneous erection
without erotic stimulation. The drug can be used while taking alcohol and is characterized by a convenient dosage
regimen – daily in the morning regardless of food intake.
Taufon® Vita
Indication: Nutritional supplement which influences on eye function
Biologically active substance: taurine (2-2 aminoethansulfonic acid).
The experiments have showed that taurine regulated the following
processes in the body:
Visual organ and central nervous system: taurine participates in
luminous transmission in retina and regulates nerve impulse
conduction velocity. Taurine is the major amino-acid component of
pigmented layer of retina and exercises protection (antioxidative) and
membrane-stabilizing action. Taurine deficiency is observed in severe
dystrophic retinal damage and optic nerve atrophy in visual organ
tissue.
Body as the whole:
Ensures the transport of substances through cell membranes and
supports electrolytic balance in respect of potassium, sodium,
magnesium, and calcium ion balance.
Activates metabolic processes, including energy, fat, and carbohydrate metabolism.
Due to these effects taurine is successfully used for visual organ, cardiovascular, nervous system function improvement in patients with
carbohydrate metabolism disorder and gerontologic practice.
Presentation:
Capsules with fill weight 350 mg that corresponds to 250 mg of taurine in 1 capsule. x 30 and x 60.
Recommendations for use:
In adults for improved eye tissue nutrition.
In all adults doing intense work on the computer and reading on mobile computers in moving transport.
During intense driving and broadcast viewing.
During long open solar radiation exposure.
Ellastenga® active glucosamine
Indication: Nutritional supplement – source of active glucosamine
Composition: Glucosamine sulphate
Biologically active substance: Glucasamine sulphate
Biologically active substance:
Glucasamine sulphate.
Improves joint mobility.
Stimulates cartilaginous tissue regeneration.
Prevents osteoarthrosis and slows down its progression.
Produces moderate anti-inflammatory and analgetic effects.
Presentation:
Capsules 750 mg x 30.
Recommendations for use:
In case of joint diseases (osteoarthrosis) with pain. syndrome,
clicking, and stiffness.
Ellastenga® contains active glucosamine in a dose of 750 mg.
Glucosamine is a structural substance of cartilaginous tissue; the deficiency of glucosamine leads to the deficiency of
physiologic properties of cartilage and joint disorder. Ellastenga® contains high quality glucosamine sulfate that
ensures its activity and effective action. Ellastenga® compensates glucosamine contents in the body and contributes
to cartilaginous tissue regeneration and easiness of movements.
Innovative approach to life
Promo-Med LLC
13, Prospect Mira, Moscow, 129090, Russia
Telеfon: + 7 (495) 640-25-28
Fax: +7 (495) 640-25-27
www.promo-med.ru